Experience With Subcutaneous PD-L1 Inhibitor
Panelists discuss the IMscin001 trial findings, which established the noninferiority of subcutaneous atezolizumab with comparable efficacy and safety to the intravenous (IV) formulation.
They highlight operational challenges, including creating multiple electronic medical record (EMR) order sets, standardizing injection times and volumes across products, and addressing nursing workflow considerations during the 2- to 10-minute injection periods.
Atezolizumab Subcutaneous Data and Implementation Considerations
The subcutaneous formulation of atezolizumab, a PD-L1 inhibitor, received approval approximately 1 year ago based on the IMscin001 phase 3 open-label study findings.
Author's summary: Panel discusses atezolizumab subcutaneous formulation.More News
- Kayla Harrison's manager: There's a lot of beef with Ronda Rousey
- Motivational Quotes (@spreadcheer1) / Posts / X
- 'Fuzzy buildup,' moldy peppers: Latest Kansas City-area restaurant inspections
- [Kayla Harrison shoots down Ronda Rousey comparison's ahead of her fight with Amanda Nunes]
- UFC 323’s Edson Barboza doesn’t regret featherweight move but ‘I look back and see how sick I was getting’
- The Good Quote (@thegoodquote) - Inspirational Community
- Photoshop CS6 tutorial: Color lookup
- Find Out Which Infiniti Recall Affected Nearly Half A Million Cars
- Post-Game Quotes: Duke
- UFC 323’s Edson Barboza doesn’t regret featherweight move but ‘I look back and see how sick I was getting’